Therapeutic efficacy of a multi-epitope vaccine against Helicobacter pylori infection in BALB/c mice model

Vaccine

Volumn 27, Issue 36, 2009, Pages 5013-5019

  Zhou, Wei Ying ^a   Shi, Yun ^a   Wu, Chao ^a   Zhang, Wei Jun ^a   Mao, Xu Hu ^a   Guo, Gang ^a   Li, Hai Xia ^a   Zou, Quan Ming ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Epitope vaccine; Helicobacter pylori; Therapeutic immunization

Indexed keywords

EPITOPE; ESCHERICHIA COLI ENTEROTOXIN; PHOSPHATE BUFFERED SALINE; RECOMBINANT HUEPI LTB VACCINE; RECOMBINANT HUEPI VACCINE; RECOMBINANT LTB VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGENICITY; ARTICLE; BACTERIAL COLONIZATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMORAL IMMUNITY; IMMUNIZATION; INFECTION CONTROL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL TOXINS; BACTERIAL VACCINES; CD4-POSITIVE T-LYMPHOCYTES; ENTEROTOXINS; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; VACCINES, SYNTHETIC;

EID: 67650467717     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.05.009     Document Type: Article

References (38)

1. Blaser M.J. Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. J Infect Dis 161 4 (1990) 626-633
2. Uemura N., Okamoto S., Yamamoto S., Matsumura N., Yamaguchi S., Yamakido M., et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345 11 (2001) 784-789
3. Wheeldon T.U., Hoang T.T., Phung D.C., Bjorkman A., Granstrom M., and Sorberg M. Long-term follow-up of Helicobacter pylori eradication therapy in Vietnam: reinfection and clinical outcome. Aliment Pharmacol Ther 21 8 (2005) 1047-1053
4. Baldari C.T., Lanzavecchia A., and Telford J.L. Immune subversion by Helicobacter pylori. Trends Immunol 26 4 (2005) 199-207
5. Sbai H., Mehta A., and DeGroot A.S. Use of T cell epitopes for vaccine development. Curr Drug Targets Infect Disord 1 3 (2001) 303-313
6. Sette A., and Fikes J. Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr Opin Immunol 15 4 (2003) 461-470
7. Lu Y., Ding J., Liu W., and Chen Y.H. A candidate vaccine against influenza virus intensively improved the immunogenicity of a neutralizing epitope. Int Arch Allergy Immunol 127 3 (2002) 245-250
8. Liu Z., and Chen Y.H. Design and construction of a recombinant epitope-peptide gene as a universal epitope vaccine strategy. J Immunol Methods 285 1 (2004) 93-97
9. Yang X.L., Liu W.C., Yang W.W., Zhong D., Liu Y.H., Zhang J.D., et al. Oral immunization of mice with vaccine of attenuated Salmonella typhimurium expressing Helicobacter pylori urease B subunit. Biomed Environ Sci 18 6 (2005) 411-418
10. Carlsohn E., Nystrom J., Bolin I., Nilsson C.L., and Svennerholm A.M. HpaA is essential for Helicobacter pylori colonization in mice. Infect Immun 74 2 (2006) 920-926
11. Nystrom J., and Svennerholm A.M. Oral immunization with HpaA affords therapeutic protective immunity against H. pylori that is reflected by specific mucosal immune responses. Vaccine 25 (14) March (2007) 2591-2598
12. Smythies L.E., Novak M.J., Waites K.B., Lindsey J.R., Morrow C.D., and Smith P.D. Poliovirus replicons encoding the B subunit of Helicobacter pylori urease protect mice against H. pylori infection. Vaccine 23 (7) January (2005) 901-909
13. Shi Y., Wu C., Zhou W.Y., Mao X.H., Guo G., and Zou Q.M. Identification of H-2d restricted Th epitopes in Urease B subunit of Helicobacter pylori. Vaccine 25 14 (2007) 2583-2590
14. Hirota K., Nagata K., Norose Y., Futagami S., Nakagawa Y., Senpuku H., et al. Identification of an antigenic epitope in Helicobacter pylori urease that induces neutralizing antibody production. Infect Immun 69 11 (2001) 6597-6603
15. Chaturvedi G., Tewari R., Mrigank, Agnihotri N., Vishwakarma R.A., and Ganguly N.K. Inhibition of Helicobacter pylori adherence by a peptide derived from neuraminyl lactose binding adhesin. Mol Cell Biochem 228 1-2 (2001) 83-89
16. Raghavan S., Svennerholm A.M., and Holmgren J. Effects of oral vaccination and immunomodulation by cholera toxin on experimental Helicobacter pylori infection, reinfection, and gastritis. Infect Immun 70 8 (2002) 4621-4627
17. Maeda K., Yamashiro T., Minoura T., Fujioka T., Nasu M., and Nishizono A. Evaluation of therapeutic efficacy of adjuvant Helicobacter pylori whole cell sonicate in mice with chronic H. pylori infection. Microbiol Immunol 46 9 (2002) 613-620
18. Nystrom J., Raghavan S., and Svennerholm A.M. Mucosal immune responses are related to reduction of bacterial colonization in the stomach after therapeutic Helicobacter pylori immunization in mice. Microbes Infect 8 2 (2006) 442-449
19. Rossi G., Ruggiero P., Peppoloni S., Pancotto L., Fortuna D., Lauretti L., et al. Therapeutic vaccination against Helicobacter pylori in the beagle dog experimental model: safety, immunogenicity, and efficacy. Infect Immun 72 6 (2004) 3252-3259
20. Wilson C.C., Newman M.J., Livingston B.D., MaWhinney S., Forster J.E., Scott J., et al. Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy. Clin Vaccine Immunol 15 6 (2008) 986-994
21. Liu Z.Q., Xiao Y., and Chen Y.H. Epitope-vaccine strategy against HIV-1: today and tomorrow. Immunobiology 208 4 (2003) 423-428
22. Zhu D., Williams J.N., Rice J., Stevenson F.K., Heckels J.E., and Christodoulides M. A DNA fusion vaccine induces bactericidal antibodies to a peptide epitope from the PorA porin of Neisseria meningitidis. Infect Immun 76 1 (2008) 334-338
23. Cai Q.L., Peng G.Y., Bu L.Y., Lin Y.H., and Wang H. A polyepitope malaria vaccine randomly constructed by epitope shuffling. Am J Trop Med Hyg 73 6 (2005) 339
24. De Groot A.S., McMurry J., Marcon L., Franco J., Rivera D., Kutzler M., et al. Developing an epitope-driven tuberculosis (TB) vaccine. Vaccine 23 17-18 (2005) 2121-2131
25. Ermak T.H., Giannasca P.J., Nichols R., Myers G.A., Nedrud J., Weltzin R., et al. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J Exp Med 188 12 (1998) 2277-2288
26. Romagnani S. Th1/Th2 cells. Inflamm Bowel Dis 5 4 (1999) 285-294
27. D'Elios M.M., Manghetti M., De Carli M., Costa F., Baldari C.T., Burroni D., et al. T helper 1 effector cells specific for Helicobacter pylori in the gastric antrum of patients with peptic ulcer disease. J Immunol 158 2 (1997) 962-967
28. Sawai N., Kita M., Kodama T., Tanahashi T., Yamaoka Y., Tagawa Y., et al. Role of gamma interferon in Helicobacter pylori-induced gastric inflammatory responses in a mouse model. Infect Immun 67 1 (1999) 279-285
29. Saldinger P.F., Porta N., Launois P., Louis J.A., Waanders G.A., Bouzourene H., et al. Immunization of BALB/c mice with Helicobacter urease B induces a T helper 2 response absent in Helicobacter infection. Gastroenterology 115 4 (1998) 891-897
30. Ikewaki J., Nishizono A., Goto T., Fujioka T., and Mifune K. Therapeutic oral vaccination induces mucosal immune response sufficient to eliminate long-term Helicobacter pylori infection. Microbiol Immunol 44 1 (2000) 29-39
31. Mohammadi M., Nedrud J., Redline R., Lycke N., and Czinn S.J. Murine CD4 T-cell response to Helicobacter infection: TH1 cells enhance gastritis and TH2 cells reduce bacterial load. Gastroenterology 113 6 (1997) 1848-1857
32. Kopitar A.N., Stegel V., Tepes B., Gubina M., Novakovic S., and Ihan A. Specific T cell responses to Helicobacter pylori predict successful eradication therapy. J Infect 54 3 (2007) 257-261
33. Akhiani A.A., Pappo J., Kabok Z., Schon K., Gao W., Franzen L.E., et al. Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells. J Immunol 169 12 (2002) 6977-6984
34. Corthesy-Theulaz I.E., Hopkins S., Bachmann D., Saldinger P.F., Porta N., Haas R., et al. Mice are protected from Helicobacter pylori infection by nasal immunization with attenuated Salmonella typhimurium phoPc expressing urease A and B subunits. Infect Immun 66 2 (1998) 581-586
35. Morihara F., Hifumi E., Yamada M., Nishizono A., and Uda T. Therapeutic effects of molecularly designed antigen UREB138 for mice infected with Helicobacter pylori. Biotechnol Bioeng 100 4 (2008) 634-643
36. Sutton P., Wilson J., Kosaka T., Wolowczuk I., and Lee A. Therapeutic immunization against Helicobacter pylori infection in the absence of antibodies. Immunol Cell Biol 78 1 (2000) 28-30
37. Lee C.K., Weltzin R., Thomas Jr. W.D., Kleanthous H., Ermak T.H., Soman G., et al. Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J Infect Dis 172 1 (1995) 161-172
38. Yano A., Onozuka A., Asahi-Ozaki Y., Imai S., Hanada N., Miwa Y., et al. An ingenious design for peptide vaccines. Vaccine 23 17-18 (2005) 2322-2326